Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma
Author
Wechsler, Michael ESzefler, Stanley J
Ortega, Victor E
Pongracic, Jacqueline A
Chinchilli, Vernon
Lima, John J
Krishnan, Jerry A
Kunselman, Susan J
Mauger, David
Bleecker, Eugene R
Bacharier, Leonard B
Beigelman, Avraham
Benson, Mindy
Blake, Kathryn V
Cabana, Michael D
Cardet, Juan-Carlos
Castro, Mario
Chmiel, James F
Covar, Ronina
Denlinger, Loren
DiMango, Emily
Fitzpatrick, Anne M
Gentile, Deborah
Grossman, Nicole
Holguin, Fernando
Jackson, Daniel J
Kumar, Harsha
Kraft, Monica
LaForce, Craig F
Lang, Jason
Lazarus, Stephen C
Lemanske, Robert F
Long, Dayna
Lugogo, Njira
Martinez, Fernando
Meyers, Deborah A
Moore, Wendy C
Moy, James
Naureckas, Edward
Olin, J Tod
Peters, Stephen P
Phipatanakul, Wanda
Que, Loretta
Raissy, Hengameh
Robison, Rachel G
Ross, Kristie
Sheehan, William
Smith, Lewis J
Solway, Julian
Sorkness, Christine A
Sullivan-Vedder, Lisa
Wenzel, Sally
White, Steven
Israel, Elliot
Affiliation
Univ Arizona Hlth SciIssue Date
2019-09-26
Metadata
Show full item recordPublisher
MASSACHUSETTS MEDICAL SOCCitation
Wechsler, M. E., Szefler, S. J., Ortega, V. E., Pongracic, J. A., Chinchilli, V., Lima, J. J., ... & Bacharier, L. B. (2019). Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. New England Journal of Medicine, 381(13), 1227-1239.Journal
NEW ENGLAND JOURNAL OF MEDICINERights
Copyright © 2019 Massachusetts Medical Society. All rights reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Morbidity from asthma is disproportionately higher among black patients than among white patients, and black patients constitute the minority of participants in trials informing treatment. Data indicate that patients with inadequately controlled asthma benefit more from addition of a long-acting beta-agonist (LABA) than from increased glucocorticoids; however, these data may not be informative for treatment in black patients. Methods: We conducted two prospective, randomized, double-blind trials: one involving children and the other involving adolescents and adults. In both trials, the patients had at least one grandparent who identified as black and had asthma that was inadequately controlled with low-dose inhaled glucocorticoids. We compared combinations of therapy, which included the addition of a LABA (salmeterol) to an inhaled glucocorticoid (fluticasone propionate), a step-up to double to quintuple the dose of fluticasone, or both. The treatments were compared with the use of a composite measure that evaluated asthma exacerbations, asthma-control days, and lung function; data were stratified according to genotypic African ancestry. ResultsWhen quintupling the dose of fluticasone (to 250 mu g twice a day) was compared with adding salmeterol (50 mu g twice a day) and doubling the fluticasone (to 100 mu g twice a day), a superior response occurred in 46% of the children with quintupling the fluticasone and in 46% of the children with doubling the fluticasone and adding salmeterol (P=0.99). In contrast, more adolescents and adults had a superior response to added salmeterol than to an increase in fluticasone (salmeterol-low-dose fluticasone vs. medium-dose fluticasone, 49% vs. 28% [P=0.003]; salmeterol-medium-dose fluticasone vs. high-dose fluticasone, 49% vs. 31% [P=0.02]). Neither the degree of African ancestry nor baseline biomarkers predicted a superior response to specific treatments. The increased dose of inhaled glucocorticoids was associated with a decrease in the ratio of urinary cortisol to creatinine in children younger than 8 years of age. Conclusions: In contrast to black adolescents and adults, almost half the black children with poorly controlled asthma had a superior response to an increase in the dose of an inhaled glucocorticoid and almost half had a superior response to the addition of a LABA. (Funded by the National Heart, Lung, and Blood Institute; BARD ClinicalTrials.gov number, NCT01967173.)Note
6 month embargo; published online: 26 September 2019ISSN
0028-4793PubMed ID
31553835Version
Final published versionSponsors
National Heart, Lung, and Blood Institute, United States Department of Health & Human Services, National Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1905560
